I. COMMENCED TRADING IN OCTOBER | ||||||||
Company (Symbol)# |
Date Filed | Date Comm. | Shares/Units (M) | Price | Shares Out (M)@ | Lead, Other Underwriters | Gross (US$M) | Post-Offering Market Cap (M)% |
INITIAL OFFERINGS | ||||||||
Omeros Corp. (OMER)1 | 1/9/08 | 10/8/09 | 6.82S | $10 | 21.3 | Deutsche Bank Sec. Wedbush PacGrow Canaccord Adams Chicago Investment Group National Securities Needham & Co. LLC |
$68.2 | $213 |
Talecris Biotherapeutics Inc. (TLCR)2 | 7/2/09 | 10/1/09 | 28.9S | $19 | 119.8 | Morgan Stanley Goldman Sachs (co-lead) Citibank (co-lead) J.P. Morgan (co-lead) Wells Fargo Sec. Barclays Capital UBS Investment Bank |
$549.1 | $2.3B |
Total: $617.3M Number of IPOs in October: 2Average value of October IPOs: $308.65M Number of IPOs in 2009: 5Total raised in IPOs in 2009: $709.9M Average value of IPOs in 2009: $141.98M | ||||||||
FOLLOW-ON OFFERINGS | ||||||||
Company (Symbol)# | Date Filed | Date Comm. | Shares/ Units (M) | Price | Shares Out (M)@ | Lead, Other Underwriters | Gross (US$M) | Post-Offering Market Cap (M)% |
Allos TherapeuticsInc. (ALTH)3 | 10/6 | 10/7 | 14S | $7.10 | 103.4 | J.P. Morgan Securities Citigroup Global Markets (co-lead) Leerink Swann (co-lead) JMP Securities Needham & Co. RBC Capital Markets |
$99.4 | $734.14 |
AspenBio Pharma Inc. (APPY)4 | 10/7 | 10/7 | 5.155S | $1.70 | 37.5 | ThinkEquity LLC | $8.8 | $63.75 |
Clinical Data Inc. (CLDA)5 | 6/28/07 | 10/28 | 2.75S | $17.25 | 26.4 | Piper Jaffray Wedbush PacGrow BMO Capital Markets Roth Capital Partners |
$47.4 | $455.4 |
Dyax Corp. (DYAX)6 | 9/30 | 10/6 | 5.5S | $3.83 | 78 | Jefferies & Co. Inc. | $21.1 | $298.7 |
Eurand NV (the Netherlands; EURX)7 | 10/22 | 10/22 | 2S | $11.25 | 47.8 | Deutsche Bank Sec. BofA Merrill Lynch (co-lead) Cowen and Co. Thomas Weisel Partners |
$22.5 | $537.75 |
Lexicon Pharmaceuticals Inc. (LXRX)8 | 9/18 | 10/9 | 22.8S | $1.50 | 173.68 | Morgan Stanley Thomas Weisel Partners |
$34.2 | $260.52 |
Nanosphere Inc. (NSPH)9 | 10/19 | 10/19 | 5.405S | $7 | 27.6 | Piper Jaffray & Co. | $37.835 | $193.2 |
Sangamo BioSciences Inc. (SGMO)10 | 6/16 | 10/7 | 3S | $7.20 | 44.3 | Jefferies & Co. | $21.6 | $318.96 |
Savient Pharmaceuticals Inc. (SVNT)11 | 10/10/07 | 10/9 | 4.95S | $13.29 | 66.6 | J.P. Morgan WedBush PacGrow (lead) Lazard Capital Markets |
$65.79 | $885.11 |
Targacept Inc. (TRGT)12 | 10/8 | 10/8 | 2.2S | $21 | 27.5 | Deutsche Bank Sec. | $46.2 | $577.5 |
Total: $404.83M Number of follow-on offerings in October: 10 Number of follow-on offerings in 2009: 43 Average value of follow-ons in 2009: $108.97M | ||||||||
Notes: # Unless otherwise indicated, shares are traded on the Nasdaq exchange. @ This column reflects the shares outstanding following the offering, when disclosed.% Market capitalization is calculated based on the offering price. Currency conversions are based on exchange rates at the time of the deal.1 Omeros' overallotment option: 1.02M shares. 2 Talecris raised a total of $950M in its IPO, with Cerberus Partners and Ampersand Ventures selling 21.1M shares and the company selling 28.9M shares, for a total of 50M shares sold. The company's $549.1M portion of the total is going directly to pay down debt. Later in the month, the underwriters exercised in full a 6M-share overallotment option granted by the selling stockholders. 3 Allos' overallotment option: 2.1M shares. 4 Includes AspenBio's overallotment option: 672,391 shares. 5 Clinical Data's overallotment option: 412,500 shares. 6 Dyax's overallotment option: 825,000 shares. 7 Eurand's shareholders also offered 6.5M shares as part of the offering, plus another 1.275M to cover overallotments. 8 Includes Lexicon's overallotment option: 2.98M shares. Lexicon concurrently placed 15.46M shares with its largest stockholder. 9 Includes Nanosphere's overallotment option: 705,000 shares. 10 Sangamo's overallotment option: 450,000 shares. 11 Includes Savient's overallotment option: 645,000 shares. 12 Targacept's overallotment option: 320,000 shares. | ||||||||
II. FILED AND PENDING | ||||||||
Company (Symbol)# | Date Filed | Shares/Units (M) | Price | Shares Out | Lead, Other Underwriters (M)@ | Gross (US$M) | ||
INITIAL OFFERINGS | ||||||||
Aldagen Inc. (ALDH) | 10/29/09 | N/A | N/A | N/A | Cowen & Co. Wells Fargo Sec. |
$80.5 | ||
Anthera Pharmaceuticals (ANTH) | 9/15/09 | N/A | N/A | 16.7 | Deutsche Bank Sec. Piper Jaffray Wedbush PacGrow Life Sci. Merriman Curhan Ford |
$70 | ||
Human Stem Cell Institute (Russia)1 | 10/7/09 | 15S | RUB 9-RUB 11 (30 cents-37 cents) | N/A | N/A | $5.025 | ||
Prometheus Laboratories Inc. (RXDX) | 12/19/07 | N/A | N/A | N/A | Goldman Sachs & Co. Credit Suisse (co-lead) Banc of America Securities Cowen & Co. Pacific Growth Equities LLC |
$100 | ||
Notes: # Unless otherwise indicated, shares are traded on the Nasdaq exchange; general shelf registration statements are not included until action is taken on the filing. * Stock symbols for companies seeking to complete IPOs are proposed. @ This column reflects the shares outstanding following the offering, when disclosed. N/A = Not available, applicable or reported. The value of all offerings is based on either the midpoint of the price range listed in the company's SEC filing or the most recent closing stock price before the offering was announced. In some cases, the company has not disclosed the number of shares to be offered or a price range. Then, the value is the maximum aggregate offering price listed in the SEC filing.1 Human Stem Cell's IPO is filed for the Moscow Interbank Currency Exchange. | ||||||||